GlassScriptPhysician profile
Dan Michael Pineda
NPI 1407370083
$2,755.25
in general payments reported to CMS, 2019-2025
12 companies · $348 in 2025
The $348 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $919 · 2023: $412 · 2024: $1,077 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,533 · Travel and Lodging: $249 · Education: $55.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,532.59 |
| Travel and Lodging | $248.63 |
| Education | $55.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,111.56 | 2022-2025 | |
| Genentech USA, INC. | $506.33 | 2022-2024 | Ocrevus, Enspryng |
| Genzyme Corporation | $221.20 | 2022-2024 | |
| Emd Serono, INC. | $184.30 | 2025 | |
| Horizon Therapeutics Plc | $176.11 | 2022-2023 | Uplizna |
| Alexion Pharmaceuticals, INC. | $165.84 | 2022-2023 | Soliris |
| Gilead Sciences, INC. | $110.54 | 2022 | |
| Biogen, INC. | $93.13 | 2024 | Vumerity |
| Jazz Pharmaceuticals INC. | $86.87 | 2022 | |
| Tg Therapeutics, INC. | $48.00 | 2025 | |
| Genentech, INC. | $30.08 | 2025 | Ocrevus |
| Astrazeneca Pharmaceuticals LP | $21.29 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Michael Pineda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.